Propranolol disposition in chronic liver disease: a physiological approach

Area of Science:

• Pharmacology
• Hepatology
• Drug Metabolism

Background:

• Propranolol pharmacokinetics are influenced by several biological determinants.
• Chronic liver disease can significantly alter these determinants.
• Understanding these alterations is crucial for managing drug therapy in liver disease patients.

Purpose of the Study:

• To quantitatively explain propranolol pharmacokinetics on a physiological basis.
• To elucidate the impact of chronic liver disease on propranolol disposition.
• To evaluate the 'intact hepatocyte theory' in the context of liver disease.

Main Methods:

• Physiological modeling of drug metabolism.
• Analysis of drug binding and hepatic blood flow.
• Assessment of hepatic circulation anatomy.

Main Results:

• Propranolol pharmacokinetics can be predicted by intrinsic clearance, hepatic blood flow, drug binding, and hepatic circulation.
• Chronic liver disease causes predictable changes in propranolol disposition by affecting these determinants.
• The 'intact hepatocyte theory' provides a framework for understanding these drug disposition changes.

Conclusions:

• Propranolol pharmacokinetics are physiologically explainable.
• Chronic liver disease significantly impacts drug disposition through alterations in key biological determinants.
• The 'intact hepatocyte theory' offers a valid explanation for observed changes in drug metabolism in liver disease.